Education
About Us
Working with TipRanks
Follow Us
Immatics (IMTX)
NASDAQ:IMTX
IMTX Stock Chart & Stats
$10.34
<$0.01(0.14%)
At close: 4:00 PM EST
$10.34
<$0.01(0.14%)
Day’s Range― - ―
52-Week Range$3.30 - $12.41
Previous CloseN/A
Volume408.80K
Average Volume (3M)344.73K
Market Cap
$1.39B
Enterprise Value$853.09M
Total Cash (Recent Filing)$430.84M
Total Debt (Recent Filing)$16.38M
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Mar 25, 2026EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding134,063,830
10 Day Avg. Volume335,429
30 Day Avg. Volume344,730
Financial Highlights & Ratios
PEG Ratio-0.44
Price to Book (P/B)1.30
Price to Sales (P/S)4.79
P/FCF Ratio-4.28
Enterprise Value/Market Cap0.62
Enterprise Value/Revenue10.07
Enterprise Value/Gross Profit10.07
Enterprise Value/Ebitda-8.02
Forecast
1Y Price Target
$20.00Price Target Upside93.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.53
Revenue Forecast (FY)$43.50M
Bulls Say, Bears Say
Bulls Say
Strong Clinical Efficacy Signals In IMA203CD8Durable objective responses and high disease control in heavily pre-treated patients indicate meaningful clinical activity for IMA203CD8. Sustained responses and manageable tolerability support a tumor‑agnostic development path, increasing long‑term regulatory and commercial potential across PRAME cancers.
Multi‑modality PRAME Franchise And Pipeline DepthA coordinated franchise across TCR‑T and bispecific modalities spreads technical and indication risk. Pipeline breadth from preclinical to early clinical stages enables multiple value inflection points and partnership opportunities, strengthening Immatics' strategic position in precision PRAME targeting.
Conservative Leverage And Low Reported DebtVery low debt provides financial flexibility during capital‑intensive clinical development, lowering insolvency risk and preserving optionality to fund trials or partnerships. This durable balance sheet conservatism supports continued R&D investment amid revenue volatility.
Bears Say
Persistent Negative Revenue Growth And MarginsSignificant and sustained revenue declines with deeply negative margins limit the firm's ability to self‑fund development and reduce operating resilience. Over months to years, weak top‑line trends increase reliance on external capital and constrain strategic investments and commercialization readiness.
Negative Operating Cash Flow And Cash Generation IssuesNegative operating cash flow reflects ongoing cash burn from clinical programs. Structural cash generation shortfalls necessitate recurring financings, raising dilution and financing‑risk over the medium term and limiting the company's ability to scale manufacturing or commercial activities independently.
High R&D Spend Driving Recurring Material LossesElevated and persistent R&D expenses are essential for progress but produce sizable quarterly losses. Over several quarters, this increases dependency on external funding, raises dilution risk, and amplifies execution risk if clinical setbacks delay milestones or commercialization, stressing long‑term sustainability.
Immatics News
IMTX FAQ
What was Immatics’s price range in the past 12 months?
Immatics lowest stock price was $3.30 and its highest was $12.41 in the past 12 months.
What is Immatics’s market cap?
Immatics’s market cap is $1.39B.
When is Immatics’s upcoming earnings report date?
Immatics’s upcoming earnings report date is Mar 25, 2026 which is in 23 days.
How were Immatics’s earnings last quarter?
Immatics released its earnings results on Nov 17, 2025. The company reported -$0.495 earnings per share for the quarter, missing the consensus estimate of -$0.441 by -$0.054.
Is Immatics overvalued?
According to Wall Street analysts Immatics’s price is currently Undervalued.
Does Immatics pay dividends?
Immatics does not currently pay dividends.
What is Immatics’s EPS estimate?
Immatics’s EPS estimate is -0.49.
How many shares outstanding does Immatics have?
Immatics has 134,063,830 shares outstanding.
What happened to Immatics’s price movement after its last earnings report?
Immatics reported an EPS of -$0.495 in its last earnings report, missing expectations of -$0.441. Following the earnings report the stock price went down -7.157%.
Which hedge fund is a major shareholder of Immatics?
Currently, no hedge funds are holding shares in IMTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immatics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.00 (93.42% Upside)
$20.00 (93.42% Upside)
Blogger Sentiment
Bullish
IMTX Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 178.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.2%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
136.07%
12-Months-Change
Fundamentals
Return on Equity
-29.00%
Trailing 12-Months
Asset Growth
-5.42%
Trailing 12-Months
Company Description
Immatics
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
IMTX Stock 12 Month Forecast
Average Price Target
$20.00
▲(93.42% Upside)
Technical Analysis
Ownership Overview
―
Insiders
9.57% Mutual Funds
49.42% Other Institutional Investors
40.51% Public Companies and
Individual Investors